Diagnostic value of immune indicators and cytokines in sepsis after percutaneous nephrolithotomy (PCNL)
Immune indicators and cytokines in sepsis after PCNL
Abstract
Objective: To analyze the changes in and diagnostic value of immune indicators and cytokines in patients with sepsis after percutaneous nephrolithotomy (PCNL).
Methods: Clinical information was gathered from 405 calculi patients who underwent PCNL at our facility between January 2021 and December 2024. The patients were divided into a sepsis group (12 patients) and a nonsepsis group (393 patients) on the basis of whether sepsis occurred after the operation. The levels of CD4+/CD8+ cells, the neutrophil-to-lymphocyte ratio (NLR), soluble trigger receptor-1 (sTREM-1) in myeloid cells, procalcitonin (PCT), tumor necrosis factor α (TNF-α), and interleukin-6 (IL-6) were measured in the two patient groups. The predictive value of the above indicators for sepsis was analyzed via receiver operating characteristic (ROC) curves.
Results: The number of patients with staghorn calculi in the sepsis group was greater than that in the nonsepsis group (P<0.05). The NLR and sTREM-1 level were greater in the sepsis group than in the nonsepsis group (all P<0.05), and the CD4+/CD8+ ratio was lower in the sepsis group than in the nonsepsis group (P<0.05). The levels of serum IL-6, TNF-α and PCT in the sepsis group were greater than those in the nonsepsis group (all P<0.05). The area under the curve (AUC) for the combined prediction of sepsis after PCNL by each index was 0.996, with a predictive sensitivity of 91.3% and a specificity of 98.4%.
Conclusion: The NLR, sTREM-1, IL-6, TNF-α and PCT in patients with sepsis after PCNL increased, whereas the CD4+/CD8+ ratio decreased. The combined detection of these levels is beneficial for guiding the early clinical prediction of the occurrence of postoperative sepsis in patients with PCNL.
References
2.Chen X, Li S, Shi C, Zhang W, Liu Z, Jiang J, Zhang Y, Chen Z, Zheng B, Zhu H. Risk factors and predictors of urogenous sepsis after percutaneous nephrolithotomy for idiopathic calcium oxalate nephrolithiasis. Transl Androl Urol. 2023 Jun 30;12(6):1002-1015. doi: 10.21037/tau-23-219. Epub 2023 Jun 26. PMID: 37426597; PMCID: PMC10323449.
3.Qiu Z, Zhan S, Song Y, Huang L, Xie J, Qiu T, Zhao C, Wang L, Li D. Construction and validation of the nomogram predictive model for postpercutaneous nephrolithotomy urinary sepsis. World J Urol. 2024 Mar 13;42(1):135. doi: 10.1007/s00345-024-04828-2. PMID: 38478045.
4.Hao X, Wang X, Wei H, Ding H, Zheng S, Wang L, Li Z, Yin H. Development and Validation of the Prediction Model of Sepsis in Patients After Percutaneous Nephrolithotomy and Sepsis Progresses to Septic Shock. J Endourol. 2023 Apr;37(4):377-386. doi: 10.1089/end.2022.0384. Epub 2023 Jan 23. PMID: 36585859.
5.Puia D, Gheorghincă Ş, Radavoi GD, Jinga V, Pricop C. Can we identify the risk factors for SIRS/sepsis after percutaneous nephrolithotomy? A meta-analysis and literature review. Exp Ther Med. 2023 Jan 25;25(3):110. doi: 10.3892/etm.2023.11809. PMID: 36793328; PMCID: PMC9923362.
6.Sun JX, Xu JZ, Liu CQ, Xun Y, Lu JL, Xu MY, An Y, Hu J, Li C, Xia QD, Wang SG. A Novel Nomogram for Predicting Post-Operative Sepsis for Patients With Solitary, Unilateral and Proximal Ureteral Stones After Treatment Using Percutaneous Nephrolithotomy or Flexible Ureteroscopy. Front Surg. 2022 Apr 15;9:814293. doi: 10.3389/fsurg.2022.814293. PMID: 35495750; PMCID: PMC9051077.
7.Shen R, Ming S, Qian W, Zhang S, Peng Y, Gao X. A novel postpercutaneous nephrolithotomy sepsis prediction model using machine learning. BMC Urol. 2024 Feb 2;24(1):27. doi: 10.1186/s12894-024-01414-x. PMID: 38308308; PMCID: PMC10837989.
8.Arslan B, Kinik AH, Gonultas S, Kose MG, Kardas S, Cetin B, Kecebas A, Altay D, Ozdemir E. Predictive value of Controlling Nutritional Status score and Prognostic Nutritional Index for systemic inflammatory response syndrome/sepsis after percutaneous nephrolithotomy. Int Urol Nephrol. 2023 May;55(5):1101-1107. doi: 10.1007/s11255-023-03559-4. Epub 2023 Mar 20. PMID: 36940002.
9.Hou HF, Liu Y, Zhang X, Han Z, Chen T. The value of postoperative HLA-DR expression and high mobility group box 1 level in predictive diagnosis of sepsis in percutaneous nephrolithotomy surgery. Ren Fail. 2022 Dec;44(1):1338-1344. doi: 10.1080/0886022X.2022.2107541. PMID: 35930298; PMCID: PMC9359155.
10.Kriplani A, Pandit S, Chawla A, de la Rosette JJMCH, Laguna P, Jayadeva Reddy S, Somani BK. The neutrophil‒lymphocyte ratio (NLR), platelet‒lymphocyte ratio (PLR) and lymphocyte‒monocyte ratio (LMR) are used to predict systemic inflammatory response syndrome (SIRS) and sepsis after percutaneous nephrolithotomy (PNL). Urolithiasis. 2022 Jun;50(3):341-348. doi: 10.1007/s00240-022-01319-0. Epub 2022 Mar 4. PMID: 35246692; PMCID: PMC9110452.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Wang L, Li D, He W, Shi G, Zhai J, Cen Z, Xu F, Xie H, Yu Z, Zhao G, Mo C, Lv Q, Tian W. Development and validation of a predictive model for postpercutaneous nephrolithotomy urinary sepsis: a multicenter retrospective study. Minerva Urol Nephrol. 2024 Jun;76(3):357-366. doi: 10.23736/S2724-6051.23.05396-X. Epub 2023 Oct 23. PMID: 37870479.
13.Qi S, Huang S, Qian R. Predictive Value of Combined Serum Nuclear Factor Erythroid 2-Related Factor 2 and Prognostic Nutritional Index for Sepsis after Percutaneous Nephrolithotomy. J Endourol. 2025 Mar;39(3):222-230. doi: 10.1089/end.2024.0519. Epub 2025 Feb 18. PMID: 39964774.
14.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
15.Zuo YT, Liu TZ, Li B, Li S, Wang YZ, Chen P, Wang XH, Wu ZH. Zero-Intrarenal Pressure Percutaneous Nephrolithotomy for One-Stage Treatment of Non-Acute Infectious Calculous Pyonephrosis: A Strategy to Avert Sepsis. J Endourol. 2024 Nov;38(11):1128-1133. doi: 10.1089/end.2024.0115. Epub 2024 Sep 6. PMID: 39212652.
16.Hobbs KJ, Bayless R, Sheats MK. A Comparative Review of Cytokines and Cytokine Targeting in Sepsis: From Humans to Horses. Cells. 2024 Sep 5;13(17):1489. doi: 10.3390/cells13171489. PMID: 39273060; PMCID: PMC11394191.
17.Kühn D, Heinen N, Sutter K, Herrmann ST, Nocke MK, Todt D, Burbelo PD, Steinmann E, Ziehe D, Koos B, Adamzik M, Putensen C, Zarbock A, Gravemann U, Jork C, Pfaender S; SepsisDataNet.NRW and CovidDataNet.NRW research group. Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival. J Med Virol. 2024 Oct;96(10):e29935. doi: 10.1002/jmv.29935. PMID: 39323094; PMCID: PMC11535095.
18.Schmidt T, Kahn R, Kahn F. Ascorbic acid attenuates activation and cytokine production in sepsis-like monocytes. J Leukoc Biol. 2022 Sep;112(3):491-498. doi: 10.1002/JLB.4AB0521-243R. Epub 2022 Feb 9. PMID: 35141934; PMCID: PMC9543185.
19.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
20.Saldaña-Gastulo JJC, Llamas-Barbarán MDR, Coronel-Chucos LG, Hurtado-Roca Y. Cytokine hemoadsorption with CytoSorb® in patients with sepsis: a systematic review and meta-analysis. Crit Care Sci. 2023 Apr-Jun;35(2):217-225. doi: 10.5935/2965-2774.20230289-en. PMID: 37712812; PMCID: PMC10406402.
21.Wang J, Wen D, Zeng S, Du J, Cui L, Sun J, Chen G, Zeng L, Du D, Zhang L, Deng J, Jiang J, Zhang A. Cytokine Biomarker Phenotype for Early Prediction and Triage of Sepsis in Blunt Trauma Patients. J Surg Res. 2023 Mar;283:824-832. doi: 10.1016/j.jss.2022.10.059. Epub 2022 Dec 5. PMID: 36915009.
22.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
23.Wang D, Wang K, Liu Q, Liu M, Zhang G, Feng K, Wang K, Ding X, Zhu H, Yang S, Liu Y, Li T, Gong P, Wang M, Wang PG, Jin H, Zhao W, Yu F. A Novel Drug Candidate for Sepsis Targeting Heparanase by Inhibiting Cytokine Storm. Adv Sci (Weinh). 2024 Aug;11(29):e2403337. doi: 10.1002/advs.202403337. Epub 2024 May 29. PMID: 38810101; PMCID: PMC11304236.
24.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
25.Hurtado RR, Sanchez-Pinto LN. Metabolomic and cytokine profiles of high-risk sepsis phenotypes in children. Sci Rep. 2025 Jul 15;15(1):25639. doi: 10.1038/s41598-025-10665-z. PMID: 40665001; PMCID: PMC12264046.
26.Chen X, Chen X, Yang Y, Luo N, Yang J, Zhong L, Guo T, Yuan Z, Wei Q, Wang C. Protective role of the novel cytokine Metrnl/interleukin-41 in host immunity defense during sepsis by promoting macrophage recruitment and modulating Treg/Th17 immune cell balance. Clin Immunol. 2023 Sep;254:109690. doi: 10.1016/j.clim.2023.109690. Epub 2023 Jul 7. PMID: 37423488.
27.Liang J, Su Y, Wang N, Wang X, Hao L, Ren C. A meta-analysis of the association between inflammatory cytokine polymorphism and neonatal sepsis. PLoS One. 2024 Jun 7;19(6):e0301859. doi: 10.1371/journal.pone.0301859. PMID: 38848433; PMCID: PMC11161124.
28.Koc S, Hanikoglu F, Dokur M, Polat Y, Celebi S, Koc SG, Kupeli I, Uysal H. Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in COVID-19 Patients with and without Bacterial Sepsis. Clin Lab. 2022 Oct 1;68(10). doi: 10.7754/Clin.Lab.2022.211249. PMID: 36250840.
Copyright (c) 2025 Yiheng Jin, Yamei Li, Xiaoyu Zhang, Bing Han, Xingshi Yan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.